...
首页> 外文期刊>Scandinavian journal of gastroenterology. >Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction
【24h】

Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction

机译:通过实时扩增耐火突变体系逆转录 - 聚合酶链反应定量乙型肝炎氨基酸取代70和91在核心编码区中

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. The effects of hepatitis C virus (HCV) sequence variations on the success of antiviral therapy or the development of hepatocellular carcinoma (HCC) are complex for many reasons. Recently, there have been several reports on the effects of genotype 1b HCV core amino acid substitutions 70 and/or 91 on the outcome of antiviral therapies and the clinical course. The purpose of this study was to establish real-time amplification refractory mutation system (ARMS) reverse transcription (RT)-polymerase chain reaction (PCR) assays for easy detection of these HCV mutations. Material and methods. Plasmids p-core-W, including the wild-type HCV core coding region (70R and 91L), and p-core-M, including the mutant-type HCV core (70Q and 91M), were constructed by cloning and PCR-based mutagenesis for control vector of the wild-type core and that of the mutant core, respectively. Using serially diluted forms of these vectors, SyBr Green-based real-time ARMS RT-PCR detection with each of the specific primer pairs was performed. Results. Each primer could clearly distinguish the difference between p-core-W and p-core-M at the same copy numbers. Concerning substitution 70, the ratios 100:1, 10:1, 1:1, 1:10, and 1:100 of p-core-W versus p-core-M could be distinguished, while for substitution 91, the ratios 100:1, 10:1, 1:1, 1:10, 1:100, and 1:1000 could be distinguished, confirming the sensitivity and specificity of the assay. Conclusions. This method could be a useful alternative for the detection of genotype 1b HCV core amino acid substitutions 70 and 91 and be reliably applied for rapid screening
机译:客观的。丙型肝炎病毒(HCV)序列变异对抗病毒治疗成功或肝细胞癌(HCC)的发育的影响是复杂的许多原因。最近,有几次关于基因型1B HCV核心氨基酸取代70和/或91对抗病毒治疗结果和临床过程的影响的报告。本研究的目的是建立实时扩增难治突变体系(臂)逆转录(RT) - 聚合酶链反应(PCR)测定,以便于检测这些HCV突变。材料与方法。通过克隆和基于PCR基于基于基于突出的HCV核心编码区(70R和91L)和包括突变型HCV芯(70Q和91M)的P-Core-W,包括突变型HCV芯(70Q和91M)的质粒分别对控制野生型核心的诱变和突变核心的诱变。使用这些载体的连续稀释形式,进行SYBR绿色的实时臂RT-PCR检测与每个特定引物对进行。结果。每个引物可以清楚地区分P-Core-W和P-Core-M之间的差异在相同的拷贝数。关于替代70,比率100:1,10:1,1:1,1:10和1:100的P-Core-W与P-Core-M相对于核心-M可以区分,而对于替换91,比率100 :1,10:1,1:1,1:10,1:100和1:1000可以区分,确认测定的敏感性和特异性。结论。该方法可以是检测基因型1B HCV核酸氨基酸取代70和91的有用替代方案,并可靠地施加用于快速筛选

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号